Royalty Report: Drugs, Cancer, Therapeutic – Collection: 267745

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 20

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 20

Primary Industries

  • Drugs
  • Cancer
  • Therapeutic
  • Drug Discovery
  • Genome
  • Disease
  • Medical
  • Semiconductors
  • Fabrication
  • Pharmaceuticals
  • Antibody
  • cardiac
  • Orthopedic
  • Diabetes Treatment
  • Supply
  • Technical Know How
  • Research
  • Specialty
  • Diagnostic
  • Tissue
  • Radiation
  • Device

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 267745

License Grant
The Company granted to Chinese Licensee an exclusive license to develop and commercialize the antibody-drug conjugate IMMU-132 (sacituzumab govitecan) (the Product) in the People’s Republic of China, Taiwan, Hong Kong, Macao, Indonesia, Philippines, Vietnam, Thailand, South Korea, Malaysia, Singapore and Mongolia.
License Property
The product ,IMMU-132 (sacituzumab govitecan), relates to a metastatic triple negative breast cancer indication for patients who have received at least 2 prior anti-cancer therapies in a metastatic setting.
Field of Use
This agreement pertains to the drug industry

IPSCIO Record ID: 233450

License Grant
The Parties intend to develop in Asia a therapeutic product containing glufosfamide for the treatment of cancer.

The Japanese Licensor grants an exclusive license to Licensors Know-How to make, have made, use, offer to sell, sell and import Compound Product throughout the world.

License Property
The Compound shall mean glufosfamide.

The Compound Product shall mean any product that was developed by Licensee or a sublicensee of Licensee for marketing as a therapeutic that contains the Compound and that is for the treatment of cancer.

Field of Use
The Field shall mean all human cancer therapeutic uses.

IPSCIO Record ID: 236353

License Grant
The Parties intend to develop in Asia a therapeutic product containing glufosfamide for the treatment of cancer.

The Japanese Licensor grants an exclusive license to Licensors Know-How to make, have made, use, offer to sell, sell and import Compound Product throughout the world.

License Property
The Compound shall mean glufosfamide.

The Compound Product shall mean any product that was developed by Licensee or a sublicensee of Licensee for marketing as a therapeutic that contains the Compound and that is for the treatment of cancer.

Field of Use
The Field shall mean all human cancer therapeutic uses.

IPSCIO Record ID: 27456

License Grant
The Company licensed certain trademarks and technology, and granted to a company headquartered in Kanagawa Prefecture, Japan the exclusive right to manufacture and sell in Japan, Korea, Taiwan, Hong Kong, China, India, the Philippines, Thailand, Vietnam, Malaysia, Singapore and Indonesia, and such other countries as the parties may agree to from time to time, products similar to those manufactured and distributed by the Company.
License Property
The Company designs, develops, manufactures, markets and services chemical mechanical planarization, or CMP, systems used in the fabrication of semiconductor devices as well as other high throughput precision surface processing systems used in the fabrication of thin film memory disk media, semiconductor wafers and general industrial components; products include polishing, grinding and lapping equipment and systems; cleaning systems; other high precision surface processing equipment; and certain other products used in its customers’ manufacturing process, including slurries.

IPSCIO Record ID: 230791

License Grant
Licensor grants to the Licensee of Japan, an exclusive license, even as against Licensor, its Affiliates and its Sub licensees, under the Licensed Technology, to use, develop, distribute, market, sell, export and import the Compound, the Product and/or the Finished Product within the Territory.
License Property
Licensor is developing a polyglutamate paclitaxel product candidate known as PGTXL or CT-2103.

Compound shall mean PG-TXL and/or CT-2103, as may be modified from time-to-time by Licensor, also known as Poly-(L)-glutamic acid paclitaxel conjugate.

Field of Use
The field of use is for treating cancer.

IPSCIO Record ID: 6729

License Grant
Licensor and Licensee entered into a License Agreement relating to Nimotuzumab.  Under this License Agreement, the Licensor exclusively Sub-Licensed to the Licensee the patent rights and related know-how for Nimotuzumab for the treatment of cancer in humans, for development, use and sale in Thailand, Singapore, Indonesia, Taiwan, Myanmar, Cambodia, Laos, Brunei, Philippines, Malaysia, African Republic of the Congo, Nigeria and South Africa.
License Property
Patents and know-how arising during the term of the Agreement are owned by the generating party. For the term of the Agreement, the Parties have agreed to grant to each other, an exclusive, fully-paid and royalty-free License to any arising intellectual property, in order to research, develop, make, have made, import, use, sell or otherwise deal in any products containing Nimotuzumab. The Licensee is responsible for the development and commercialization of Nimotuzumab in the agreed upon countries, in accordance with a written research and development plan, and for all costs in connection therewith.  
The Innogene License Agreement requires Innogene to purchase 100% of its supplies of Nimotuzumab for non-clinical and clinical studies and trials and 100% of its commercial supplies of Nimotuzumab from Licensor.

Patent
Technology 80.02.113
Improved Treatment Method for Cancer
  80.02.113.20

    US
  Abandoned
  627,836
  1887-39    
  80.02.113.4
    
  US
  Issued
  08/25/98
  5,798,339
  1887-79
  80.02.113.7
    
  US
  Issued
  04/08/97
  5,618,846  
  1887-134    
  80.02.113.6
    
    
  US    
  Issued
  05/05/98    
  5,747,543    
  1887-133    
  80.02.113.8
    
    
  US    
  Issued
  01/12/99    
  5,859,065    
  1887-184    
  80.02.113.2
    
    
    
  US    
  Abandoned    
  09/200,783    
  1887-190    
  80.02.113.14
    
  80.02.171.6    
  US    
  Under
  review at Patent Office    
  08/505,269    
  1887-148
  
80.02.171.12    
  US    
  Under
  review at Patent Office    
  08/773,987    
  1887-174  
    
  80.02.171.13    
  Australia    
  Issued
  02/17/94    
  693,780    
  1887-149

    Patent
Technology 80.02.194
    Method
of Treatment of Hormone-Unresponsive Metastatic Prostate Cancer
    
  File    
  Country  
  Status  
  Ser./Pat.#  
  Attorney
  Reference  
  
    
  80.02.194.1    
  US    
  Issued
  07/11/95    
  5,432,168    
  1887-93  
  
    
  80.02.194.2    
  PCT  
  Entered
  Natl. Phase    
  CA94/00676  
  1887-119

  80.02.194.9    
  US  
  Issued
  01/26/99  
  5,863,912  
  1887-164

Field of Use
The rights granted apply to the healthcare industry relating to cancer in humans.

IPSCIO Record ID: 257476

License Grant
For Licensors intellectual property, Licensor grants the Licensee of China an exclusive right and license under Licensors Intellectual Property applicable to the Licensed Product to develop, manufacture, market, sell, use, offer for sale and import the Licensed Product in the Territory during the term of this Agreement.

Licensor grants the right of access, the right of reference and the right to use and incorporate all information provided to Licensee pursuant to obtaining the regulatory approval of the Licensed Product within the Territory and in performing the development, commercialization and all Licensees obligations in respect of the Licensed Product under this Agreement.

License Property
Licensor has intellectual property relating to liposomal irinotecan.

Product shall mean any pharmaceutical composition comprising liposomally encapsulated Irinotecan (( + )-(S)-4, 11-Diethyl-4, 12-dihydro-4-hydroxy-3, 14-dioxo-1 Hpyrano[3, 46,7)indolizino[L2-b]chinolin-9-yl[l,4 -bipiperidin el-1- carboxylate, CAS 97682-44-5). including salts thereof.

The patents are for Liposomes Useful for Drug Delivery.

Irinotecan is a cancer medicine that interferes with the growth and spread of cancer cells in the body. Irinotecan is used to treat cancers of the colon and rectum. It is usually given with other cancer medicines in a combination chemotherapy.

Field of Use
Irinotecan is used as a chemotherapy drug.

IPSCIO Record ID: 257617

License Grant
This amendment addresses new parent for Licensor, territories and royalties.

With the original agreement, Licensors intellectual property, Licensor grants the Licensee of China an exclusive right and license under Licensors Intellectual Property applicable to the Licensed Product to develop, manufacture, market, sell, use, offer for sale and import the Licensed Product in the Territory during the term of this Agreement.

Licensor grants the right of access, the right of reference and the right to use and incorporate all information provided to Licensee pursuant to obtaining the regulatory approval of the Licensed Product within the Territory and in performing the development, commercialization and all Licensees obligations in respect of the Licensed Product under this Agreement.

License Property
Licensor has intellectual property relating to liposomal irinotecan.

Product shall mean any pharmaceutical composition comprising liposomally encapsulated Irinotecan (( + )-(S)-4, 11-Diethyl-4, 12-dihydro-4-hydroxy-3, 14-dioxo-1 Hpyrano[3, 46,7)indolizino[L2-b]chinolin-9-yl[l,4 -bipiperidin el-1- carboxylate, CAS 97682-44-5). including salts thereof.

The patents are for Liposomes Useful for Drug Delivery.

Field of Use
Irinotecan is used as a chemotherapy drug.
MM-398 is a novel, stable nanotherapeutic encapsulation of the marketed chemotherapy drug irinotecan. MM-398 recently achieved its primary efficacy endpoints in Phase 2 clinical trials in pancreatic and gastric cancer.

IPSCIO Record ID: 286090

License Grant
Licensee of Japan and Licensor desire to conduct certain collaborative research.

Licensor grants to the Licensee of Japan a non-exclusive license under the Licensor Technology that is the subject of the Research Program solely to conduct the Research Program activities assigned to Licensee under the Research Plan.

Licensee shall have the exclusive right to utilize the Collaboration Technology to develop Collaboration Products for use and sale in the Licensee Territory and to commercialize the Collaboration Products in the Licensee Territory.

License Property
Dendritic Cell means a human dendritic cell or other antigen-presenting cell or other cells from which dendritic cells can be derived.

The developed intellectual property will aid in discovering new immunotherapy targets, and/or developing new dendritic cell-based immunotherapy products.

Dendritic cells (DCs) are antigen-presenting cells (also known as accessory cells) of the mammalian immune system. Their main function is to process antigen material and present it on the cell surface to the T cells of the immune system. They act as messengers between the innate and the adaptive immune systems.

Field of Use
Field means the discovery, development, manufacture, use and sale of products that generally utilize Dendritic Cell separation, antigen engineering, and antigen or antigen gene delivery to Dendritic Cells for use in human therapies that are based on, comprise, utilize or are derived from the Licensor Technology.

IPSCIO Record ID: 336294

License Grant
Licensor hereby grants to Japanese Licensee and its Affiliates the exclusive (even as to Licensor) right and license (with the right to sublicense upon prior written notice to Licensor, except that sublicensing of manufacturing rights shall require Licensors prior written approval, which approval shall not unreasonably be withheld) within the Field of Use and in the Territory under the Licensor Patent Rights and Licensor Know How to manufacture, use and sell Anti-CD4 Antibodies under Licensees trademarks or trade names, subject to the obligation to pay royalties to Licensor in accordance with Article V.

In case Licensee exercises the right to manufacture Anti-CD4 Antibodies, Licensee shall give Licensor at least eighteen (18) months prior written notice of its intention to exercise such right.

License Property
Anti-CD4 Antibodies shall mean human anti-CD4 monoclonal antibodies produced from Transgenic Mice (as hereinafter defined) and developed in the course of the Research Program (as hereinafter defined).

The Licensor is developing MDX-CD4, a HuMAb-Mouse fully human antibody, for the treatment of rheumatoid arthritis and other autoimmune disorders. MDX-CD4 binds to human CD4, which is present on the surface of certain T-cells in the human immune system. By binding to such T-cells, MDX-CD4 is designed to inactivate or reduce the ability of these cells to mediate the persistent inflammation characteristics of such autoimmune diseases. The Licensor commenced Phase I clinical trials of MDX-CD4 in 1998.

Field of Use
Field of Use shall mean the use of Anti-CD4 Antibodies in human therapy. If expanded in accordance with this Agreement, Field of Use shall also include the use of Anti-CD4 Antibodies in human diagnostics.

IPSCIO Record ID: 347182

License Grant
Licensor will grant Licensee exclusive development and commercialization rights to bempedoic acid and the bempedoic acid /ezetimibe combination tablet for purposes of treating hyperlipidemia in humans (the Field) in the following territories South Korea, Taiwan, Hong Kong, Thailand, Vietnam, Brazil, Macao, Cambodia and Myanmar (the Daiichi Territory).
License Property
Bempedoic acid and the bempedoic acid /ezetimibe combination tablet is a oral, small molecule in fixed-dose combination developed to lower elevated LDL-C (low-density lipoprotein cholesterol) to help patients who still need additional lipid lowering despite taking maximally tolerated statin therapy.
Field of Use
Field of use is for purposes of treating hyperlipidemia in humans.

Hyperlipidemia is an abnormally high concentration of fats or lipids in the blood commonly known as high cholesterol.

IPSCIO Record ID: 210064

License Grant
The Belgium Licensor granted an exclusive, royalty-bearing license to the Chinese Licensee. The Licensee will develop and commercialize the anti-RANKL Nanobody, ALX-0141, in the People’s Republic of China, Hong Kong, Macao and Taiwan for the treatment of a range of diseases, including osteoporosis and bone metastases.
License Property
The Licensors anti-RANKL Nanobody, ALX-0141 is used in the treatment of bone loss disorders.
Field of Use
The Licensee is responsible for the clinical development, registration and commercialization of anti-RANKL Nanobody therapeutics.

IPSCIO Record ID: 351975

License Grant
Licensor granted Licensee of Singapore an exclusive license to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin-6, SON-080 (the “Compound”) (such preparations, the “Products”) for the prevention, treatment or palliation of diabetic peripheral neuropathy in humans (the “DPN Field”) in Malaysia, Singapore, Indonesia, Thailand, Philippines, Vietnam, Brunei, Myanmar, Lao PDR and Cambodia (the “Exclusive Territory”).
License Property
Compound is SON-080, a specific recombinant human interleukin-6. SON-080 is a candidate in target indications of Chemotherapy-Induced Peripheral Neuropathy (CIPN) and Diabetic Peripheral Neuropathy (DPN).
Field of Use
Field of use is for the prevention, treatment or palliation of diabetic peripheral neuropathy in humans.

Peripheral neuropathy is nerve damage caused by chronically high blood sugar and diabetes. It leads to numbness, loss of sensation, and sometimes pain in your feet, legs, or hands. It is the most common complication of diabetes.

IPSCIO Record ID: 370599

License Grant
Licensee from Cayman Islands obtained an exclusive, sublicensable license under certain patents and know-how of Licensor to develop, manufacture, use, sell, import and commercialize Licensor’s proprietary SHP2 inhibitor, BBP-398 (formerly known as IACS-15509) in the licensed territory of Mainland China, Hong Kong, Macau, Taiwan, Thailand, Singapore, and South Korea, in the licensed field of diagnostic, prophylactic, palliative, and therapeutic uses or indications in humans.
License Property
SHP2 inhibitor (BBP-398) (formerly known as IACS-15509) is an orally available allosteric inhibitor of SHP2, a tyrosine phosphatase that plays a key role in the RTK-mediated MAPK signal transduction pathway.
Field of Use
Licensed field is for diagnostic, prophylactic, palliative, and therapeutic uses or indications in humans including for the potential treatment of MAPK-driven solid tumors.

MAPK (mitogen-activated protein kinase) pathway is a central axis driving aberrant proliferation in a broad spectrum of cancers.

IPSCIO Record ID: 288274

License Grant
Licensor of Japan and Licensee desire to conduct certain collaborative research.

The Licensor of Japan grants a non-exclusive license under any applicable Licensor know-how and Patent rights solely to conduct the Research Program activities assigned to Licensee under the Research Plan.

For the Commercial License, Licensor grants to the exclusive license in the License Territory under the Collaboration Technology to research, develop, make, have made, use, sell, offer for sale and import Collaboration Products and Licensee Products in the Licensee Territory.

Licensee shall have the exclusive right to utilize the Collaboration Technology to develop and commercialize Collaboration Products in the Licensee Territory.

License Property
Dendritic Cell means a human dendritic cell or other antigen-presenting cell or other cells from which dendritic cells can be derived.

Dendritic cells (DCs) are antigen-presenting cells (also known as accessory cells) of the mammalian immune system. Their main function is to process antigen material and present it on the cell surface to the T cells of the immune system. They act as messengers between the innate and the adaptive immune systems.

The developed intellectual property will aid in discovering new immunotherapy targets, and/or developing new dendritic cell-based immunotherapy products.

Field of Use
Field means the discovery, development, manufacture, use and sale of products that generally utilize Dendritic Cell separation, antigen engineering, and antigen or antigen gene delivery to Dendritic Cells for use in human therapies that are based on, comprise, utilize or are derived from the Licensee Technology.

IPSCIO Record ID: 109724

License Grant
This is an agreement between the Licensor and the Japanese Licensee, a 50 /50 joint
venture, to produce laboratory animals and/or feed for laboratory animals.
License Property
The Licensor has technology in the field of laboratory animals and/or feed for laboratory animals and/or equipment.

The Licensor are a global market leader in the commercial production and supply of animal research models, meaning whole, living animals bred in a clean environment specifically for the purpose of research, most of which are rats and mice, for use in the discovery, development and testing of new pharmaceuticals.

Field of Use
Licensee will produce laboratory animals and/or feed and/ or equipment.

IPSCIO Record ID: 152770

License Grant
Licensor grants to the Japanese Licensee a perpetual, exclusive license, with the right to grant sublicenses, under Licensors Patents and know-how to make, have made, use, sell and have sold product and finished product within the field and territories.
License Property
Patents and know-how are relating to products directed against Macrophage Migration Inhibitory Factor (MIF), and the use of such products for the potential palliation, evaluation, diagnosis and treatment and/or prophylaxis of human disease states which are caused or exacerbated by MIF.  The products are those in which composition of matter contains antibodies against MIF.

Macrophage migration inhibitory factor (MIF or MMIF), also known as glycosylation-inhibiting factor (GIF), L-dopachrome isomerase, or phenylpyruvate tautomerase is a protein that in humans is encoded by the MIF gene.

Field of Use
The field shall mean use of the products for in vivo therapy of human disease and in vivo diagnosis and in vitro diagnosis and evaluation of human tissue or fluid.

IPSCIO Record ID: 301681

License Grant
Licensor granted Licensee an exclusive license to develop and commercialize Toca 511 & Toca FC within the greater China region, including mainland China, Hong Kong, Macao and Taiwan (the Licensed Territory).
License Property
Toca 511 (vocimagene amiretrorepvec) & Toca FC (extended-release flucytosine) is for the treatment of recurrent high grade glioma (HGG), a brain cancer.

Licensor is a clinical-stage, cancer-selective gene therapy company developing broadly applicable product candidates designed to activate a patient’s immune system against their own cancer.

Field of Use
The products are for use in the treatment of brain cancer.  The Licensee is dedicated to developing and commercializing cutting-edge innovative oncology drugs to address the unmet medical needs of cancer patients in China.

IPSCIO Record ID: 372929

License Grant
Licensor granted to the Licensee of the Cayman Islands an exclusive license under certain patents and know-how of Licensor to develop and commercialize Licensor’s proprietary product NBTXR3 in the territory of Mainland China, Macau, Hong Kong, Thailand, Taiwan, South Korea and Singapore, in the licensed field of use of a product activated by radiotherapy in oncology. Licensee will participate in a global phase III registrational study in head and neck cancer for the licensed product and four additional registrational studies across indications and therapeutic combinations. We are obligated to use commercially reasonable efforts to enroll a certain percentage of study patients in the territory in such studies.
License Property
NBTXR3, a radiosensitizer designed to be injected directly into a malignant tumor prior to standard radiotherapy. When exposed to ionizing radiation, NBTXR3 has been shown to enhance the localized effect of radiotherapy. NBTXR3 is designed to enhance the effect of radiotherapy without resulting in additional side effects on surrounding healthy tissue. NBTXR3 may also prime the body’s immune response against cancer, and clinical activity has been observed across a number of different solid tumor types and in combination with immuno-oncology agents. Clinical proof of concept for NBTXR3 has been demonstrated in soft tissue sarcoma.
Field of Use
Field of Use is for radiotherapy treatment in oncology.

IPSCIO Record ID: 7417

License Grant
Licensor agrees to grant and does hereby grant to Licensee, a South Korean company, an exclusive license, in the Territory, under the Licensed Technology, to make, have made, use, market, sell, offer to sell and otherwise transfer and provide Licensed Product.
License Property
Owner has developed a device that delivers heat to a localized area of the body in order to relieve pain associated with stings from insects and sea creatures that deliver thermolabile venom; such device is known by its tradename of THERAPIK®;

The term 'Licensed Technology' refers to technology covered by patent #4,944,297 Portable apparatus for localized heating of the skin for therapeutic purposes.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.